000162869 001__ 162869
000162869 005__ 20230915092412.0
000162869 0247_ $$2doi$$a10.15252/emmm.202114745
000162869 0247_ $$2pmid$$apmid:34309222
000162869 0247_ $$2pmc$$apmc:PMC8422075
000162869 0247_ $$2ISSN$$a1715-4684
000162869 0247_ $$2ISSN$$a1757-4676
000162869 0247_ $$2ISSN$$a1757-4684
000162869 0247_ $$2altmetric$$aaltmetric:110478633
000162869 037__ $$aDZNE-2021-01524
000162869 041__ $$aEnglish
000162869 082__ $$a610
000162869 1001_ $$00000-0002-6073-8811$$aEmmenegger, Marc$$b0
000162869 245__ $$aLAG3 is not expressed in human and murine neurons and does not modulate α-synucleinopathies.
000162869 260__ $$aHeidelberg$$bEMBO Press$$c2021
000162869 3367_ $$2DRIVER$$aarticle
000162869 3367_ $$2DataCite$$aOutput Types/Journal article
000162869 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655469967_22303
000162869 3367_ $$2BibTeX$$aARTICLE
000162869 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000162869 3367_ $$00$$2EndNote$$aJournal Article
000162869 500__ $$a(CC BY)
000162869 520__ $$aWhile the initial pathology of Parkinson's disease and other α-synucleinopathies is often confined to circumscribed brain regions, it can spread and progressively affect adjacent and distant brain locales. This process may be controlled by cellular receptors of α-synuclein fibrils, one of which was proposed to be the LAG3 immune checkpoint molecule. Here, we analysed the expression pattern of LAG3 in human and mouse brains. Using a variety of methods and model systems, we found no evidence for LAG3 expression by neurons. While we confirmed that LAG3 interacts with α-synuclein fibrils, the specificity of this interaction appears limited. Moreover, overexpression of LAG3 in cultured human neural cells did not cause any worsening of α-synuclein pathology ex vivo. The overall survival of A53T α-synuclein transgenic mice was unaffected by LAG3 depletion, and the seeded induction of α-synuclein lesions in hippocampal slice cultures was unaffected by LAG3 knockout. These data suggest that the proposed role of LAG3 in the spreading of α-synucleinopathies is not universally valid.
000162869 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000162869 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000162869 650_7 $$2Other$$aLAG3
000162869 650_7 $$2Other$$aneurodegeneration
000162869 650_7 $$2Other$$aprionoids
000162869 650_7 $$2Other$$aα-synuclein
000162869 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000162869 650_2 $$2MeSH$$aAnimals
000162869 650_2 $$2MeSH$$aHumans
000162869 650_2 $$2MeSH$$aMice
000162869 650_2 $$2MeSH$$aMice, Transgenic
000162869 650_2 $$2MeSH$$aNeurons
000162869 650_2 $$2MeSH$$aParkinson Disease
000162869 650_2 $$2MeSH$$aSynucleinopathies
000162869 650_2 $$2MeSH$$aalpha-Synuclein: genetics
000162869 7001_ $$00000-0002-0148-2596$$aDe Cecco, Elena$$b1
000162869 7001_ $$00000-0002-9253-4362$$aHruska-Plochan, Marian$$b2
000162869 7001_ $$0P:(DE-2719)2811141$$aEninger, Timo$$b3$$udzne
000162869 7001_ $$00000-0002-1894-1859$$aSchneider, Matthias M$$b4
000162869 7001_ $$0P:(DE-2719)2812097$$aBarth, Melanie$$b5$$udzne
000162869 7001_ $$00000-0001-9189-3390$$aTantardini, Elena$$b6
000162869 7001_ $$ade Rossi, Pierre$$b7
000162869 7001_ $$0P:(DE-2719)2810940$$aBacioglu, Mehtap$$b8$$udzne
000162869 7001_ $$aLangston, Rebekah G$$b9
000162869 7001_ $$aKaganovich, Alice$$b10
000162869 7001_ $$00000-0002-3700-0464$$aBengoa-Vergniory, Nora$$b11
000162869 7001_ $$aGonzalez-Guerra, Andrès$$b12
000162869 7001_ $$00000-0003-4665-5558$$aAvar, Merve$$b13
000162869 7001_ $$00000-0002-3282-4042$$aHeinzer, Daniel$$b14
000162869 7001_ $$aReimann, Regina$$b15
000162869 7001_ $$0P:(DE-2719)2811581$$aHäsler, Lisa M$$b16$$udzne
000162869 7001_ $$aHerling, Therese W$$b17
000162869 7001_ $$aMatharu, Naunehal S$$b18
000162869 7001_ $$00000-0002-8399-4009$$aLandeck, Natalie$$b19
000162869 7001_ $$00000-0002-6591-6269$$aLuk, Kelvin$$b20
000162869 7001_ $$00000-0003-0000-7096$$aMelki, Ronald$$b21
000162869 7001_ $$0P:(DE-2719)2810803$$aKahle, Philipp J$$b22$$udzne
000162869 7001_ $$00000-0002-2674-9891$$aHornemann, Simone$$b23
000162869 7001_ $$aKnowles, Tuomas P J$$b24
000162869 7001_ $$00000-0002-1058-3831$$aCookson, Mark R$$b25
000162869 7001_ $$aPolymenidou, Magdalini$$b26
000162869 7001_ $$0P:(DE-2719)2000010$$aJucker, Mathias$$b27$$udzne
000162869 7001_ $$00000-0002-0344-6708$$aAguzzi, Adriano$$b28
000162869 773__ $$0PERI:(DE-600)2485479-7$$a10.15252/emmm.202114745$$gVol. 13, no. 9$$n9$$pe14745$$tEMBO molecular medicine$$v13$$x1757-4684$$y2021
000162869 8564_ $$uhttps://pub.dzne.de/record/162869/files/DZNE-2021-01524.pdf$$yOpenAccess
000162869 8564_ $$uhttps://pub.dzne.de/record/162869/files/DZNE-2021-01524.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000162869 909CO $$ooai:pub.dzne.de:162869$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000162869 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811141$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000162869 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812097$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000162869 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810940$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000162869 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811581$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b16$$kDZNE
000162869 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810803$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b22$$kDZNE
000162869 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000010$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b27$$kDZNE
000162869 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000162869 9141_ $$y2021
000162869 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-02-04
000162869 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000162869 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000162869 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000162869 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-02-04
000162869 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000162869 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-02-04
000162869 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-29
000162869 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-29
000162869 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-07-19T13:19:31Z
000162869 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-07-19T13:19:31Z
000162869 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review, Double blind peer review$$d2021-07-19T13:19:31Z
000162869 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-29
000162869 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-29
000162869 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-29
000162869 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEMBO MOL MED : 2021$$d2022-11-29
000162869 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bEMBO MOL MED : 2021$$d2022-11-29
000162869 9201_ $$0I:(DE-2719)1210001$$kAG Jucker$$lCell Biology of Neurologic Diseases$$x0
000162869 9201_ $$0I:(DE-2719)1210000-4$$kAG Kahle 2$$lFunctional Neurogenetics$$x1
000162869 980__ $$ajournal
000162869 980__ $$aVDB
000162869 980__ $$aUNRESTRICTED
000162869 980__ $$aI:(DE-2719)1210001
000162869 980__ $$aI:(DE-2719)1210000-4
000162869 9801_ $$aFullTexts